Tags : AI-Based


InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will […]Read More